Terminé

Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est collecté

Médicament Data

Médicament
Qui peut participer

Maladie de la valve aortique+12

+ Sténose aortique sous-valvulaire

+ Sténose de la valve aortique

Voir tous les critères d'éligibilité
Comment se déroule l'étude

Observationnel
Date de début : septembre 1996
Voir le détail du protocole

Résumé

Sponsor principalNational Heart, Lung, and Blood Institute (NHLBI)
Dernière mise à jour : 4 mars 2008
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 septembre 1996

Date à laquelle le premier participant a commencé l'étude.

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease characterized by left ventricular (LV) hypertrophy. There is often associated LV diastolic dysfunction and myocardial ischemia. The severity of the LV hypertrophy, diastolic dysfunction, and myocardial ischemia are important determinants of clinical outcomes. Angiotensin II modulates cell growth and cardiac function. There is also increasing evidence that the renin-angiotensin system (RAS) may be present in cardiac cells, and the hypertrophic action of angiotensin II could therefore be mediated by circulating or locally produced hormone. Animal and clinical studies have demonstrated that independent of their effects on systemic blood pressure, ACE inhibition and angiotensin II receptor (AT1) blockade can reduce cardiac hypertrophy, improve LV diastolic function and myocardial ischemia. AT1 blockade may be preferable to ACE inhibitors because by inhibiting angiotensin II from binding to its receptor, the system can be turned off irrespective of the source of angiotensin II. Also, there may be fewer side effects due to lack of bradykinin. This is a double-blind, placebo-controlled study that examines the abilities of enalapril (ACE inhibition) and losartan (AT1 blockade), separately or in combination, to cause regression of the cardiac hypertrophy, and to improve LV function and myocardial perfusion in non-obstructive HCM.

NCT00001534
Sponsor principalNational Heart, Lung, and Blood Institute (NHLBI)
Dernière mise à jour : 4 mars 2008
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

112 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Maladie de la valve aortiqueSténose aortique sous-valvulaireSténose de la valve aortiqueMaladies CardiovasculairesMaladies CardiaquesCardiomégalieMaladies des Valves CardiaquesCardiomyopathiesConditions pathologiques, signes et symptômesMaladies vasculairesConditions pathologiques anatomiquesCardiomyopathie hypertrophiqueHypertrophieIschémie myocardiqueHypertrophie du ventricule gauche

Critères

INCLUSION CRITERIA HCM of either gender, aged 20-55 years. Non-dilated LV (LVIDd less than 60 mm) with LV wall thickness of greater than or equal to 16 mm measured in any LV segment by NMR. Non-obstructive HCM: A LV outflow gradient of less than or equal to 30 mm Hg gradient at rest and less than or equal to 55 mm Hg following isoproterenol infusion to a heart rate of greater than or equal to 120 beats per minute at cardiac catheterization. New York Heart Association functional class I-III. Patients who have participated in the previous toxicity study may be recruited for this study, if they wish. Patients who have previously taken an ACE inhibitor or losartan could only be included in this study, if they have been off these drugs for a period of 6 months or longer. EXCLUSION CRITERIA Severe cardiac symptoms at rest (NYHA IV). LV outflow tract gradient of greater than 30 mm Hg at rest or greater than 55 mm Hg following isoproterenol infusion to a heart rate of greater than or equal to 120 beats per minute at cardiac catheterization. Systemic diseases (respiratory, neurologic, or locomotor) that prevent exercise testing, echocardiography or NMR, MUGA, thallium studies, and cardiac catheterization. Coronary artery disease (greater than 50% arterial luminal narrowing of a major epicardial vessel) or congenital cardiovascular abnormalities (e.g. ASD, VSD, coronary anomalies). Chronic atrial fibrillation. Bleeding disorder (PTT greater than 35 sec, pro time greater than 14.7 sec, platelet count less than 154 k/mm3). Anemia (Hb less than 12.7 g/dl in males and less than 11.0 g/dl in females); renal impairment (BUN greater than 22 mg/dl and serum creatinine greater than 1.4 mg/dl); K+ less than 3.3 mmol/l or greater than 5.1 mmol/l. Hypertension: basal systolic and diastolic pressures of greater than 160 mm Hg or greater than 95 mm Hg, respectively on two occasions separated by one hour of rest. Hypotension: basal sitting systolic arterial pressure less than 100 mm Hg confirmed 30 minutes later. Must have ability to estimate LV wall thickness. Radiographic evidence of overt cardiac failure (pulmonary edema on chest X-ray). Negative urine pregnancy test. Pregnant or lactating female patients. Diminished LV systolic function (resting or exercise LV ejection fractions estimated by radionuclide angiography less than 50%). Dependence on other cardioactive drugs such as diuretics, verapamil, B-blockers, or antiarrhythmic drugs to control symptoms and arrhythmias. Negative HIV test. Sensitivity to ACE inhibitor e.g. angioedema. Must have ability to set up an outpatient monitoring system.

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

National Heart, Lung and Blood Institute (NHLBI)

Bethesda, United StatesOuvrir National Heart, Lung and Blood Institute (NHLBI) dans Google Maps
Terminé1 Centres d'Étude